MOXISYLYTE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H25NO3.ClH
Molecular Weight	315.836
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1

InChI

InChIKey=IPWGSXZCDPTDEH-UHFFFAOYSA-N

InChI=1S/C16H25NO3.ClH/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6;/h9-11H,7-8H2,1-6H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H25NO3
Molecular Weight	279.3746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459
Curator's Comment: description was created based on several sources, including https://books.google.ru/books?id=S4GJio79XOUC&pg=PA97&lpg=PA97&dq=MOXISYLYTE+%09Withdrawal&source=bl&ots=dzBbL_E8c0&sig=r1pfUZ1LhFGihzzNswfGr7f38Mg&hl=ru&sa=X&ved=0ahUKEwjNlJeazZnOAhWJnBoKHZRoC3YQ6AEIVzAJ#v=onepage&q=MOXISYLYTE%20%09Withdrawal&f=false http://www.ncbi.nlm.nih.gov/pubmed/1475074

Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction, also was studied, that this drug may be useful to treat ocular disorders such as diabetic retinopathy. It is an alpha1-adrenergic antagonist. Was developed for self-injection therapy in France and marketed in several European countries as Icavex. In the spring 2005 the manufacturer of Icavex decided to withdraw this drug from Europe market, presumable due to its low market shares.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-1 171 Target ID: CHEMBL2094251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10699651	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erectile dysfunction 35 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9711459	Primary		Withdrawn	Unknown Approved Use Unknown
Diabetic retinopathy 17 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1475074	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of adrenergic agents on the expression of zebrafish (Danio rerio) vitellogenin Ao1.	2009-07-01	19371759
Raynaud's phenomenon (primary).	2008-12-16	19445785
Noradrenergic control of GnRH release from the ewe hypothalamus in vitro: sensitivity to oestradiol.	2008-12	18484954
Raynaud's phenomenon (secondary).	2008-09-26	19445801
Oral vasodilators for primary Raynaud's phenomenon.	2008-04-16	18425964
Noradrenergic control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to oestradiol.	2008-04	18325001
Electroacupuncture-induced pressor and chronotropic effects in anesthetized rats.	2006-01-30	16459151
Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation.	2003-08	12897587
Alpha(1L)-, but not alpha(1H)-, adrenoceptor antagonist prevents allergic bronchoconstriction in guinea pigs in vivo.	2002-09-27	12323390
Assessment of the intrinsic urethral sphincter component function in postprostatectomy urinary incontinence.	2002	11948711
The esterase-like activity of serum albumin may be due to cholinesterase contamination.	2001-10	11697469
Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents.	2001-10	11678758
[Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].	2001-02	11587653
Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte.	2000-03-15	10699651
Ergotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride.	1986-01	2936675
Effects of thymoxamine and its metabolites on clonidine-induced hypotension and bradycardia in rats.	1982-07	6215903
Effect of thymoxamine and pilocarpine on the depth of the anterior chamber.	1980-10	6449278

Patents

Sample Use Guides

In Vivo Use Guide

Intracavernous injection of moxisylyte at 10, 20 or 30 mg can induce an erection adequate for intercourse in most of the patients

Route of Administration: Other

In Vitro Use Guide

Moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue was investigated and compared with other alpha-adrenergic antagonists. Moxisylyte produced a concentration-dependent relaxation of a norepinephrine-induced (1 x 10(-5) M) contraction of the corpus cavernosum tissue. Pretreatment with 1 x 10(-6) M doses of moxisylyte reduced competitively the norepinephrine-induced contraction

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:48:10 GMT 2025` Edited by `admin` on `Mon Mar 31 17:48:10 GMT 2025`
Record UNII	WK2KZM9V6X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOXISYLYTE HYDROCHLORIDE

Common Name

English

NSC-170448

Preferred Name

English

THYMOXAMINE HCL

Common Name

English

MOXISYLYTE HYDROCHLORIDE [MART.]

Common Name

English

MOXISYLYTE HYDROCHLORIDE [JAN]

Common Name

English

THYMOXAMINE HYDROCHLORIDE

Common Name

English

MOXISYLYTE HCL

Common Name

English

Moxisylyte hydrochloride [WHO-DD]

Common Name

English

MOXISYLYTE HYDROCHLORIDE [MI]

Common Name

English

6-ACETOXYTHYMOL 2-(DIMETHYLAMINO)ETHYL ETHER, HYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29713